[Ip-health] MSD and Cipla announce Partnership to Co-market MSD's raltegravir 400mg tablet for Indian Market

Shailly Gupta shailly.gupta at geneva.msf.org
Thu Feb 20 06:55:03 PST 2014

MSD that holds patent for HIV drug Raltegravir , has announced strategic
partnership with Cipla to market, promote and distribute 400mg tablet of
this drug in India. Raltegravir is used to treat patients who have developed
resistance to both first and second line regimen.

The statement issued jointly by Cipla and MSD is available at the link




More information about the Ip-health mailing list